Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


miR-450a Acts as a Tumor Suppressor in Ovarian Cancer by Regulating Energy Metabolism.

Muys BR, Sousa JF, Plaça JR, de Araújo LF, Sarshad AA, Anastasakis DG, Wang X, Li XL, de Molfetta GA, Ramão A, Lal A, Vidal DO, Hafner M, Silva WA.

Cancer Res. 2019 Jul 1;79(13):3294-3305. doi: 10.1158/0008-5472.CAN-19-0490. Epub 2019 May 17.


Highly expressed placental miRNAs control key biological processes in human cancer cell lines.

Vidal DO, Ramão A, Pinheiro DG, Muys BR, Lorenzi JCC, de Pádua Alves C, Zanette DL, de Molfetta GA, Duarte G, Silva WA Jr.

Oncotarget. 2018 May 4;9(34):23554-23563. doi: 10.18632/oncotarget.25264. eCollection 2018 May 4.


HOX genes: potential candidates for the progression of laryngeal squamous cell carcinoma.

de Barros E Lima Bueno R, Ramão A, Pinheiro DG, Alves CP, Kannen V, Jungbluth AA, de Araújo LF, Muys BR, Fonseca AS, Plaça JR, Panepucci RA, Neder L, Saggioro FP, Mamede RC, Figueiredo DL, Silva WA Jr.

Tumour Biol. 2016 Nov;37(11):15087-15096. Epub 2016 Sep 22.


Placenta-Enriched LincRNAs MIR503HG and LINC00629 Decrease Migration and Invasion Potential of JEG-3 Cell Line.

Muys BR, Lorenzi JC, Zanette DL, Lima e Bueno Rde B, de Araújo LF, Dinarte-Santos AR, Alves CP, Ramão A, de Molfetta GA, Vidal DO, Silva WA Jr.

PLoS One. 2016 Mar 29;11(3):e0151560. doi: 10.1371/journal.pone.0151560. eCollection 2016.


Myosin-Va contributes to manifestation of malignant-related properties in melanoma cells.

Alves CP, Moraes MH, Sousa JF, Pontes CLS, Ramão A, Yokoyama S, Trindade DM, Fisher DE, Espreafico EM.

J Invest Dermatol. 2013 Dec;133(12):2809-2812. doi: 10.1038/jid.2013.218. Epub 2013 May 7. No abstract available.


Changes in the expression of proteins associated with aerobic glycolysis and cell migration are involved in tumorigenic ability of two glioma cell lines.

Ramão A, Gimenez M, Laure HJ, Izumi C, Vida RC, Oba-Shinjo S, Marie SK, Rosa JC.

Proteome Sci. 2012 Sep 3;10(1):53. doi: 10.1186/1477-5956-10-53.

Supplemental Content

Support Center